CHINA PHARMA HOLDINGS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2M | $15.6M | $20.4M | $22.1M | $32.8M | $54.5M | $81.2M | $74.4M |
| Cost of Revenue | $10.7M | $12.4M | $15.8M | $17.2M | $23.4M | $38.7M | $52.2M | $44.1M |
| Gross Profit | $2.5M | $3.2M | $1.5M | $2.7M | $-480.9K | $14.1M | $29.0M | $30.3M |
| Gross Margin | 18.7% | 20.7% | 7.2% | 12.1% | -1.5% | 25.8% | 35.7% | 40.7% |
| Operating Expenses | ||||||||
| Research & Development | $90.5K | $366.0K | $961.9K | $2.8M | $1.7M | $438.7K | — | — |
| SG&A Expense | $2.0M | $2.3M | $1.9M | $1.7M | $2.4M | $2.9M | $3.7M | $3.0M |
| Operating Income | $-18.7M | $-8.2M | $-14.3M | $-38.8M | $-18.6M | $5.9M | $22.0M | $24.7M |
| Operating Margin | -141.4% | -52.4% | -70.3% | -175.1% | -56.7% | 10.8% | 27.1% | 33.2% |
| Interest Expense | $539.3K | $849.6K | $-1.2M | $785.8K | $-348.7K | $-308.4K | $-255.2K | $-168.3K |
| Pretax Income | $-19.2M | $-8.9M | $-15.3M | $-39.5M | $-18.9M | $5.6M | $22.7M | $1.4M |
| Income Tax Expense | $122.6K | $308.2K | $60.4K | $-77.0K | $-1.1M | $-983.9K | $-3.4M | $-2.7M |
| Net Income | $-19.3M | $-9.2M | $-15.4M | $-39.6M | $-20.0M | $4.6M | $19.3M | $23.4M |
| Net Margin | -145.9% | -59.0% | -75.7% | -178.7% | -61.0% | 8.5% | 23.7% | 31.5% |
| EPS (Basic) | $-0.07 | $-0.04 | $-0.06 | $-0.15 | $-0.08 | $0.02 | $0.07 | $0.09 |
| EPS (Diluted) | $-0.07 | $-0.04 | $-0.06 | $-0.15 | $-0.08 | $0.02 | $0.07 | $0.09 |
| Shares Outstanding (Basic) | 261.5M | 261.5M | 261.5M | 261.5M | 261.5M | — | — | 260.4M |
| Shares Outstanding (Diluted) | 261.5M | 261.5M | 261.5M | 261.5M | 261.5M | 261.5M | 260.9M | 260.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |